Abstract
Background
Skin and soft tissue infections (SSTIs) are caused by microbial invasion of healthy or damaged skin. SSTIs are difficult to manage and contribute to chronicity and emergence of antimicrobial resistance.
Objectives
To ascertain the prevalence of bacteria causing SSTIs and their antimicrobial susceptibility patterns.
Methods
A prospective study between November 2020 and May 2021. A total of 447 samples from SSTIs were analyzed.
Results
A total of 347 samples revealed mono-bacterial growth, of which 67% were male. SSTIs are common among patients aged 21–50 years with the dominance (78%) of gram-negative rods (GNRs). Escherichia coli (36%), Klebsiella spp. (22%), Staphylococcus aureus (16%), and Pseudomonas aeruginosa (11%) were predominant organisms. GNRs were highly resistant (>65%) to ciprofloxacin and trimethoprim–sulfamethoxazole. For injectable antibiotics, the highest resistance was determined against ceftriaxone, and the least resistance was determined against amikacin. Resistance against carbapenem was the highest among P. aeruginosa (53%) and Klebsiella spp. (32%). S. aureus showed the highest resistance against ciprofloxacin, and the least resistance was determined against clindamycin. Of 57 S. aureus isolates, 86% isolates were methicillin-resistant Staphylococcus aureus (MRSA). All isolates of P. aeruginosa and S. aureus were sensitive to polymyxin B and vancomycin, respectively. The prevalence of multidrug-resistant E. coli and Klebsiella spp. was higher among deep-seated SSTIs (dSSTIs).
Conclusions
The predominant etiology of SSTIs is GNR. Currently, there is very high resistance against oral antibiotics. Antimicrobial resistance against carbapenem has also increased. Moreover, there is a high frequency of MRSA. MDR E. coli and Klebsiella spp. isolates are frequently involved in dSSTIs.
Keywords: bacteria, drug resistance, oral, prevalence, skin, soft tissue
Skin and soft tissue infections (SSTIs) have been defined as invasion of the epidermis, dermis, and subcutaneous tissue by bacteria. The term SSTI covers infections of all anatomical and surgical sites where the integrity of the skin has been breached [1]. If SSTIs are just presented with skin redness, they are called mild or superficial SSTIs (sSSTIs), and if present along with systemic signs such as tachycardia, fever, and hypotension, they are classified as deep-seated SSTIs (dSSTIs) [2]. The Infectious Diseases Society of America (IDSA) classifies SSTIs into 2 categories: purulent infections (e.g., furuncles, carbuncles, and abscesses) and non-purulent infections (e.g., erysipelas, cellulitis, and necrotizing fasciitis) [1]. SSTIs are usually associated with prolonged hospital stay, increased medical cost, and diverse etiology. The management of dSSTIs is challenging and often requires hospitalization, incision, drainage, or debridement [3]. Predisposing factors include old age, trauma, cardio-pulmonary or hepato-renal disease, diabetes mellitus, and immunosuppression [4].
Although SSTIs affect all age groups, they are more frequent among men aged <5 years and >65 years, involving the lower leg region [5]. Annual outpatient visits for SSTIs are estimated at >14 million/year in the United States [2]. Nearly 7%–10% of admitted patients are affected by SSTIs, and they represent the third most common diagnosis after chest pain and asthma in emergencies [6].
SSTIs can be mono-microbial or poly-microbial. Methicillin-resistant Staphylococcus aureus (MRSA) has been accounted for 59% of SSTIs. Although gram-negative rods (GNRs) are often overlooked as a cause of SSTIs, several studies claim GNRs to be the dominant cause [7,8,9]. Poly-microbial infections account for 20%–30% [10].
Similarities in clinical presentation and low probability of isolating an organism make the diagnosis challenging [5]. Treatment decisions are often empirical and based on educational guess, host characteristics, likely pathogens, and local susceptibility patterns [5]. Treatments are frequently topical, oral, intravenous, or surgeries [11]. Oral formulations are preferred to avoid higher cost and adverse effects of intravenous administration. Intravenous treatment is reserved for inpatients, for life-threatening dSSTIs, or for those who are unable to absorb oral formulations or fail to achieve adequate concentration at the infection site [12].
The increase in antibiotic resistance and its rapid spread among pathogens has posed a threat to public health worldwide [10]. The growing prevalence of multidrug-resistant pathogens like MRSA and carbapenem-resistant enterobacteriaceae (CRE) is a global concern [9]. Although few studies from Pakistan report the incidence rate and antimicrobial susceptibility profile of Staphylococcus aureus (S. aureus) causing SSTIs, the data for other microbes are limited [11, 13,14,15,16,17].
Methods
Ethical approval was obtained from the Ethical Review Committee of the Sindh Institute of Urology and Transplantation (approval No. SIUT-ERC-2020/A-244). Because this was a laboratory-based study, the ERC had exempted this research from obtaining informed consent from patients.
Study design
A prospective laboratory-based study in the Department of Microbiology, Sindh Institute of Urology and Transplantation (SIUT), Pakistan, conducted from November 2020 to May 2021.
Study population
A total of 447 patients of all ages and both sexes attending out-patient clinics or admitted in wards with SSTIs were included. A physician recorded demographic characteristics and underlying cause and stratified the SSTIs into sSSTIs and dSSTIs.
Inclusion criteria
Mono-bacterial growth either gram-positive cocci (GPC) or GNRs. We used the STROBE cross-sectional checklist to report our results.
Exclusion criteria
Transplant and burns patients, poly-microbial growth, yeasts/fungus, gram-positive rods, and gram-negative cocci.
Sample collection and processing
Pus swabs, discharge/secretion, exudates, aspirate, or tissue samples from SSTIs were inoculated on the chocolate, blood, and MacConkey agar (Oxoid Ltd, Hampshire, UK).
Identification and antibiotic susceptibility testing
Bacteria were identified using standard methods, such as Gram staining, catalase, coagulase, oxidase, mannitol salt agar (MSA), DNAse, bile esculin agar, and fermentation of different sugars. Antimicrobial susceptibility was determined for only top 4 most prevalent organisms using Kirby–Bauer disk diffusion method against the following antibiotics:
(ORAL) trimethoprim–sulfamethoxazole (SXT) (25 μg), ciprofloxacin (5 μg), amoxicillin + clavulanic acid (AMC) (30 μg), erythromycin (15 μg), clindamycin (2 μg), (injectable) ceftriaxone (30 μg), amikacin (30 μg), tazobactam + piperacillin (TZP) (110 μg), sulbactam + cefoperazone (SCF) (105 μg), and (carbapenem) imipenem (10 μg).
Susceptibility to polymyxin B and vancomycin was determined using the microbroth dilution method and E test, respectively. Polymyxin B MIC interpretation was done as intermediate = 2 μg/mL and resistant = 4 μg/mL. A cefoxitin 30 μg disk was used to determine MRSA. The SCF zone diameter of ≤15 mm was interpreted as resistant, 16–20 mm as intermediate, and ≥21 mm as sensitive [18]. The Clinical Laboratory Standard Institute (CLSI) M100 guidelines were used to interpret the results [19].
Multidrug resistance
Multidrug resistance (MDR) is defined as bacterial resistance to at least 1 agent in 3 or more antimicrobial classes [7].
Data analysis
Data analysis was performed using MS excel, SPSS version 20, and GraphPad prism 9.3.1.
Results
A total of 447 specimens from 447 SSTI patients ranging in age from 1 to 78 years, with mean age of 33.76 ± 21.27 years, were included in this study. Of these, mono-microbial growth was isolated from 347 (78%) patients, of which 61% were inpatients and 39% were outpatients.
Of 347 patients, 67% were male and 33% were female. Most of the patients (157 (45%)) were in the 21–50 years age group, 26% were older than 51 years, and 18% were in the 1–20 years age group. The age data were missing for 38 (11%) patients (Table 1).
Table 1.
Demographic characteristics and distribution of cases among inpatients and outpatients suffering from sSSTIs and dSSTIs
sSSTI n = 124 (36%) | dSSTI n = 223 (64%) | Total n = 347 | ||||
---|---|---|---|---|---|---|
| ||||||
Frequency | % | Frequency | % | Frequency | % | |
Patient setting | ||||||
Inpatient | 63 | 30 | 148 | 70 | 211 | 61 |
Outpatient | 61 | 45 | 75 | 55 | 136 | 39 |
Gender | ||||||
Male | 88 | 38 | 144 | 62 | 232 | 67 |
Female | 36 | 31 | 79 | 69 | 115 | 33 |
Age (years) | ||||||
≤20 | 23 | 38 | 38 | 62 | 61 | 18 |
21–50 | 56 | 36 | 101 | 64 | 157 | 45 |
≥51 | 35 | 38 | 56 | 62 | 91 | 26 |
Underlying medical condition | ||||||
Chronic kidney disease | 47 | 37 | 80 | 63 | 127 | 37 |
Diabetes mellitus | 36 | 39 | 56 | 61 | 92 | 27 |
Malignancy | 13 | 28 | 33 | 72 | 46 | 13 |
Immunosuppression | 16 | 42 | 22 | 58 | 38 | 11 |
Chronic liver disease | 9 | 28 | 23 | 72 | 32 | 9 |
Heart failure | 3 | 25 | 9 | 75 | 12 | 3 |
SSTIs | ||||||
Wound infection | 82 | 66 | - | - | - | - |
Diabetic foot ulcer | 15 | 12 | - | - | - | - |
Impetigo | 15 | 12 | - | - | - | - |
Cellulitis | 12 | 10 | - | - | - | - |
Abscess | - | - | 138 | 62 | - | - |
Surgical site infection | - | - | 72 | 32 | - | - |
Necrotizing fasciitis | - | - | 13 | 6 | - | - |
Organisms | ||||||
E. coli | 57 | 45 | 69 | 55 | 126 | 36 |
Klebsiella spp. | 27 | 35 | 49 | 65 | 76 | 22 |
S. aureus | 14 | 24 | 43 | 76 | 57 | 16 |
Pseudomonasaeruginosa | 9 | 24 | 29 | 76 | 38 | 11 |
Proteus spp. | 7 | 58 | 5 | 42 | 12 | 3 |
Acinetobacter spp. | 5 | 45 | 6 | 55 | 11 | 3 |
Morganella morganii | 3 | 30 | 7 | 70 | 10 | 3 |
CoNS | - | - | 6 | 100 | 6 | 2 |
Enterococcus spp. | 2 | 40 | 3 | 60 | 5 | 1.4 |
Streptococcus spp. | - | - | 4 | 100 | 4 | 01 |
Aeromonas hydrophila | - | - | 1 | 100 | 1 | 0.2 |
Streptococcuspneumoniae | - | - | 1 | 100 | 1 | 0.2 |
CoNS, coagulase-negative Staphylococcus; SSTIs, skin and soft tissue infections; sSSTIs, superficial skin and soft tissue infections; dSSTIs, deep-seated skin and soft tissue infections.
The prevalence of E. coli, Klebsiella spp., Pseudomonas aeruginosa and S. aureus was significantly higher among dSSTIs (Figure 1).
Figure 1.
Prevalence of bacteria causing superficial and deep-seated SSTIs among patients attending the SIUT Hospital from November 2020 to May 2021.
Others = Proteus spp., Acinetobacter spp., Morganella morganii, Aeromonas hydrophila, CoNS, Enterococcus spp., Streptococcus spp., and Streptococcus pneumoniae. CoNS, coagulase-negative Staphylococcus.
Most of the samples in our study were dSTTIs (64%). The common sites among dSTTIs were abscess (62%) and surgical sites (32%), and the least common was necrotizing fasciitis (6%). Wound (66%) was the most common representative site for sSSTIs, followed by diabetic foot ulcer and impetigo (12% each), and cellulitis (10%). The most common underlying condition was chronic kidney disease (37%), followed by diabetes mellitus (27%), malignancy (13%), immunosuppression (11%), chronic liver disease (9%), and heart failure (3%) (Table 1). The prevalence of GNRs was higher (274 (79%)) among SSTIs than GPC. The most common isolated GNRs were E. coli (36%), Klebsiella spp. (22%), and Pseudomonas aeruginosa (11%). The most common GPC was S. aureus (16%) (Figure 1).
A number of other GNRs including Proteus spp. (3%), Acinetobacter spp. (3%), M. morganii (3%), and Aeromonas hydrophila (0.2%), and GPC including coagulase-negative Staphylococcus (CoNS) (2%), Enterococcus spp. (1.4%), Streptococcus spp. (1%), and S. pneumoniae (0.2%) were also isolated. We have limited our results and discussion to only top 4 prevalent GNRs and GPC isolates (297) (86%) (i.e., E. coli, Klebsiella spp., P. aeruginosa, and S. aureus) in this study.
For oral antibiotics, all 3 GNRs revealed a high level of resistance (>65%) against ciprofloxacin and SXT. Klebsiella spp. and E. coli showed resistance against AMC (62% and 49%), respectively.
For injectable antibiotics, the least level of resistance among each GNR was determined against amikacin, and the highest was determined against ceftriaxone. P. aeruginosa and Klebsiella spp. were highly resistant to SCF (42% and 49% respectively) and TZP (34% and 43%,). E. coli showed the highest resistance against SCF (30%) and TZP (29%), and the least resistance against amikacin (9%). None of the P. aeruginosaisolates showed resistance against polymyxin B.
For carbapenem, P. aeruginosa showed the highest resistance (53%), followed by Klebsiella spp. (32%) and E. coli (18%). S. aureus showed the highest resistance against ciprofloxacin (91%), followed by AMC (81%), erythromycin (68%), and SXT (42%) and the least resistance against clindamycin (14%). The overall prevalence of MRSA was 86%. The prevalence of MRSA among superficial and deep-seated SSTIs was 11 (78.5%) and 38 (88%), respectively. None of the S. aureus isolate was resistant to vancomycin. E. coli and Klebsiella spp. isolates from dSSTIs were comparatively more resistant to oral, injectable, and carbapenem antibiotics. Conversely, S. aureus and P. aeruginosa isolates from sSSTIs were comparatively more resistant to oral, injectable, and carbapenem antibiotics (Table 2).
Table 2.
Antimicrobial resistance pattern of common bacteria isolated from sSSTIs and dSSTIs against oral, injectable, and carbapenem antibiotics
Bacterial isolate | SSTIs | Number of resistance pathogens to antimicrobial agents, n (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
P.O. | Injectable | Carbapenem | |||||||||
| |||||||||||
SXT | CIP | AMC | E | DA | AK | TZP | SCF | CRO | IPM | ||
E. coli (n = 126) | sSSTI (n = 57) | 43 (75.4) | 42 (73.6) | 22 (38.5) | - | - | 2 (3.5) | 14 (24.5) | 13 (22.8) | 38 (66.7) | 9 (15.7) |
dSSTI (n = 69) | 48 (70) | 56 (81) | 40 (58) | - | - | 9 (13) | 23 (33) | 25 (36) | 61 (88) | 14 (20) | |
Klebsiella spp. (n = 76) | sSSTI (n = 27) | 16 (59) | 21 (77.8) | 17 (63) | - | - | 9 (33.3) | 9 (33.3) | 10 (37) | 22 (81.4) | 7 (25.9) |
dSSTI (n= 49) | 38 (78) | 40 (82) | 30 (61) | - | - | 20 (41) | 24 (49) | 27 (55) | 43 (88) | 17 (35) | |
P. aeruginosa (n = 38) | sSSTI (n = 9) | 9 (100) | 6 (66.6) | - | - | - | 4 (44.4) | 4 (44.4) | 5 (55.5) | - | 6 (66.6) |
dSSTI (n = 29) | 26 (90) | 20 (69) | - | - | - | 11 (38) | 9 (31) | 11 (38) | - | 14 (48) | |
S. aureus (n = 57) | sSSTI (n = 14) | 8 (57.1) | 13 (92.8) | 11 (78.5) | 10 (71.4) | 3 (21.4) | - | - | - | - | - |
dSSTI (n= 43) | 16 (37) | 39 (91) | 35 (81) | 29 (67) | 5 (12) | - | - | - | - | - |
−, not done; AK, amikacin; AMC, amoxicillin + clavulanic acid; CIP, ciprofloxacin; CRO, ceftriaxone; DA, clindamycin; dSSTIs, deep-seated skin and soft tissue infections; E, erythromycin; IPM, imipenem; n, number of isolates; P.O., Per os; SCF, sulbactam + cefoperazone; sSSTIs, superficial skin and soft tissue infections; SXT, trimethoprim–sulfamethoxazole; TZP, tazobactam + piperacillin.
The MDR prevalence of E. coli, Klebsiella spp., P. aeruginosa, and S. aureus was 70%, 75%, 58%, and 73% respectively. Overall, the prevalence of E. coli and Klebsiella MDR among dSSTIs was higher than that in P. aeruginosa and S. aureus, which was higher among sSSTIs (Table 3).
Table 3.
MDR pattern of bacteria isolated from sSSTIs and dSSTIs
Bacterial isolate | SSTIs | Antimicrobial classes related to number (%) | |||||
---|---|---|---|---|---|---|---|
| |||||||
R 1 | R 2 | R 3 | R 4 | ≥R5 | MDR, n (%) | ||
E. coli | sSSTI (n = 57) | 8 (14) | 8 (14) | 14 (25) | 6 (11) | 14 (25) | 34 (60) |
dSSTI (n = 69) | 4 (6) | 8 (12) | 21 (30) | 10 (14) | 23 (33) | 54 (78) | |
Klebsiella spp. | sSSTI (n = 27) | 2 (7) | 4 (15) | 5 (19) | 4 (15) | 9 (33) | 18 (67) |
dSSTI (n = 49) | 2 (4) | 4 (8) | 9 (18) | 5 (10) | 25 (51) | 39 (80) | |
P. aeruginosa | sSSTI (n = 9) | 3 (33) | 0 (0) | 1 (11) | 0 (0) | 5 (56) | 6 (66.6) |
dSSTI (n= 29) | 4 (14) | 5 (17) | 5 (17) | 2 (7) | 9 (31) | 16 (55) | |
S. aureus | sSSTI (n = 14) | 0 (0) | 1 (7) | 7 (50) | 3 (21) | 2 (14) | 12 (86) |
dSSTI (n = 43) | 2 (5) | 9 (21) | 21 (49) | 4 (9) | 5 (12) | 30 (70) |
dSSTIs, deep-seated skin and soft tissue infections; MDR, multidrug resistance; sSSTIs, superficial skin and soft tissue infections.
Discussion
In this study, mono-bacteria were isolated from 78% of patients, of which 67% were males. Similar results have been reported from Pakistan and Ethiopia with the single pathogen isolation (77% and 82%, respectively) with male dominance [11, 7]. In the present study, the incidence of SSTIs was higher (45%) among patients in the 21–50 years age group; this is in agreement with previous studies that report higher prevalence in the 15–44 years age group [11, 7]. Moreover, the rate of SSTIs was higher among inpatients (61%) in our study, which is analogous to a previous study (72.8%) [7]. In this study, dSSTIs were more common (64%), among which abscess and surgical sites were the major sites (94%), whereas wound was the most common site (66%) for sSSTIs. This was in agreement with a similar study from Pakistan, where abscess was the most common site [11]. Chronic kidney disease and diabetes mellitus were major underlying conditions (64%) in our patients. A previous study has reported diabetes mellitus, chronic kidney disease, and heart failure as the most common underlying medical conditions [8].
In the current study, the GNR/GPC ratio was 4:1. Furthermore, the prevalence rate of GNR was higher (79%) than reported in the studies conducted in India, Ethiopia, and Greece (57%, 57%, and 55%, respectively) [7,8,9]. The most frequent GNRs in this study were E. coli (36%), followed by Klebsiella spp. (22%) and P. aeruginosa (11%). The results are in concordance with a study from Pakistan that reported E. coli and P. aeruginosa from complicated SSTIs as the most frequent GNRs. Another study from India reported P. aeruginosa (21%) and E. coli (17.5%) as predominant GNRs [9]. This deviance in the isolation may be due to geographical variation or study design. S. aureus was the predominant (16%) GPC found in this study, which is in agreement with studies published from Pakistan and Nepal [11, 20].
In our study, >65% of all 3 GNRs revealed resistance against each oral antibiotic tested. This was in agreement with a similar study from Nepal that reported the majority of E. coli isolates were resistant to amoxicillin and co-trimoxazole and all E. coli isolates were resistant to ciprofloxacin [20]. A recent review from Pakistan reported the resistance pattern of E. coli against ciprofloxacin (58%–74%), co-trimoxazole (65%–82%), and co-amoxiclav (40%–92%), whereas the resistance among Klebsiella spp. was reported against ciprofloxacin (24%–86%) and co-trimoxazole (58%–69%) [17].
For injectable antibiotics, only a least number of GNRs were resistant against amikacin and a highest number were resistant against ceftriaxone in our study. We report >79% of E. coli and Klebsiella spp. were resistant against ceftriaxone. A similar high resistance rate of >80% of Klebsiella spp. and E. coli against third-generation cephalosporins has been reported [9, 11]. E. coli was found the least resistant against amikacin (9%) in this study., which is in contrast to other studies where they have ascertained a very high resistance rate among E. coli against amikacin (63%–80%). For Klebsiella spp., resistance against amikacin was 38% in our study, which is similar to the resistance reported in a study from India (40%) and higher than that reported in a study from Pakistan (25%) [9, 11]. This indicates that resistance against amikacin among Klebsiella spp. is increasing in Pakistan. In this study, 39% of P. aeruginosa demonstrated resistance against amikacin, which is lower than that reported in studies from Pakistan (66.6%) and India (47.8%) [9, 11].
In contrast to a previous study from Pakistan where resistance against TZP among Klebsiella spp., P. aeruginosa, and E. coli was reported 12.5%, 6%, and 2%, respectively. Our findings demonstrate a much higher rate of resistance, i.e., 43%, 34%, and 29%, respectively. This significant increase in resistance in our isolates may be due to the overuse of antibiotics in our hospital. However, our results are similar to those of a study from India where high resistance prevalence among E. coli (63%) and Klebsiella spp. (60%) against TZP has been reported [9, 11]. In our study, the rate of resistance among P. aeruginosa, Klebsiella spp., and E. coli to SCF was 42%, 49%, and 30%, respectively.
In this study, a very high level of resistance against carbapenem was found among P. aeruginosa (53%), Klebsiella spp. (32%), and E. coli (18%) in contrast to a previous studies from Pakistan and India where low resistance among Klebsiella spp. (0% and 0%, respectively), P. aeruginosa (8.4% and 8.6%, respectively), and E. coli (1.7 and 2.6%, respectively) has been reported. Another report form the USA and Europe also reported all E. coli isolates were sensitive to imipenem [21]. This high level of resistance against carbapenem in our region may be due to the increasing expression of extended spectrum beta-lactamases, the use of self-medication, and indiscriminate use of antibiotics. In our study, all isolates of P. aeruginosa and S. aureus were sensitive to polymyxin B and vancomycin, respectively. This may be accredited to the presence of intrinsic genes among these isolates [22].
We noticed differences in the resistance pattern of isolates from dSSTIs and sSSTIs. A comparatively high number of E. coli and Klebsiella spp. isolates were resistant from dSSTIs against oral, injectable, and carbapenem antibiotics, whereas S. aureus and P. aeruginosa isolated from sSSTIs were more resistant.
The cumulative resistance rate of bacteria from hospitalized patients was higher in our study, indicating the circulation of highly resistant bacteria, particularly MDR E. coli, Klebsiella spp., and S. aureus within the hospital environment, which alarms for continuous monitoring and isolation of patients from immunocompromised and health care workers. This was in agreement with the previous reports where a higher proportion of antimicrobial resistance among inpatients has been reported [23].
The predominant GPC in our study was S. aureus (78%). Notably, a high prevalence of MRSA (86%) was ascertained in our study population compared to that in previous studies from Pakistan (53%, 36.1%, and 42%) [24,25,26]. A meta-analysis of 37 studies from China has reported the pooled prevalence of MRSA (21.2%) [27]. This strikingly high frequency of MRSA might be attributed to the frequent use of empirical treatment for SSTIs, a paradigm shift in the daily life style due to the COVID-19 pandemic, or a typical public hospital with overuse of intravenous drugs. In our study, 74% of S. aureus were multidrug-resistant, which is lower than that reported in a previous study from Ethiopia 94.8% [20].
The high prevalence of SSTIs was found among males in the 21–50 years age group. The predominant isolates were E. coli, Klebsiella spp., P. aeruginosa, and S. aureus. More than 50% of all GNRs were resistant to each oral antibiotic. For intravenous antibiotics, the least resistance was determined against amikacin, and the highest was determined against ceftriaxone. For carbapenem, P. aeruginosa showed the highest resistance (53%). S. aureus showed the highest resistance against ciprofloxacin, and the least resistance against clindamycin. MDR E. coli and Klebsiella spp. isolates were found to be predominant among dSSTIs. We recommend continuous surveillance for appropriate antibiotic usage and for preventing the emergence of MDR pathogens.
Acknowledgments
The authors would like to thank microbiology laboratory staff of the Sindh Institute of Urology and Transplantation for allowing us to collect samples and use the laboratory facilities. The authors are also grateful to Iqbal Mujtaba and Sufiyan Ahmed for helping with data management and statistical analysis.
Footnotes
Author contributions.
RMAK, SKD, AN, and MNZ contributed substantially to the conception and design of the study. All the authors contributed substantially to the acquisition of data, analysis, and interpretation. RMAK and SKD drafted the manuscript. AN, SJ, and MNZ critically contributed to its revision for important intellectual content. All authors approved the final version submitted for publication and agreed to take responsibility for statements made in the published article.
Conflict of interest statement.
Each author has completed and submitted an International Committee for Medical Journal Editors disclosure form for potential conflicts of interest. None of the authors have disclosed any potential or actual conflict of interest related to the present article.
Data sharing statement.
Statistical summaries are presented in this published article; further details anonymized from any patient are available from the corresponding author on reasonable request.
References
- [1].Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52. doi: 10.1093/cid/ciu444. [DOI] [PubMed] [Google Scholar]
- [2].Silverberg B. A structured approach to skin and soft tissue infections (SSTIs) in an ambulatory setting. Clin Pract. 2021;11:65–74. doi: 10.3390/clinpract11010011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Alabi A, Kazimoto T, Lebughe M, Vubil D, Phaku P, Mandomando I. et al. Management of superficial and deep-seated Staphylococcus aureus skin and soft tissue infections in sub-Saharan Africa: a post hoc analysis of the StaphNet cohort. Infection. 2018;46:395–404. doi: 10.1007/s15010-018-1140-6. [DOI] [PubMed] [Google Scholar]
- [4].Ramakrishnan K, Salinas RC, Higuita NIA. Skin and soft tissue infections. Am Fam Physician. 2015;92:474–83. [PubMed] [Google Scholar]
- [5].Kaye KS, Petty LA, Shorr AF, Zilberberg MD. Current epidemiology, etiology, and burden of acute skin infections in the United States. Clin Infect Dis. 2019;68(Supplement_3):S193–9. doi: 10.1093/cid/ciz002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19:173–84. doi: 10.1155/2008/846453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Mohammed A, Seid ME, Gebrecherkos T, Tiruneh M, Moges F. Bacterial isolates and their antimicrobial susceptibility patterns of wound infections among inpatients and outpatients attending the University of Gondar Referral Hospital, Northwest Ethiopia. Int J Microbiol. 2017;2017 doi: 10.1155/2017/8953829. 8953829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Ioannou P, Tsagkaraki E, Athanasaki A, Tsioutis C, Gikas A. Gram-negative bacteria as emerging pathogens affecting mortality in skin and soft tissue infections. Hippokratia. 2018;22:23–8. [PMC free article] [PubMed] [Google Scholar]
- [9].Afroz Z, Metri BC, Jyothi P. Bacteriological profile and antimicrobial susceptibility pattern of skin and soft tissue infections among gram negative bacilli in a tertiary care hospital of South India. J Pharm Sci Res. 2015;7:397–400. [Google Scholar]
- [10].Trojan R, Razdan L, Singh N. Antibiotic susceptibility patterns of bacterial isolates from pus samples in a tertiary care hospital of Punjab, India. Int J Microbiol. 2016;2016 doi: 10.1155/2016/9302692. 9302692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Waheed A, Amar A, Afridi IA, Rauf S. Bacteriological profile and antibiotics susceptibility patterns of complicated skin and skin structure infections in tertiary care hospitals, Peshawar. J Pak Assoc Dermatol. 2020;30:580–6. [Google Scholar]
- [12].McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr. 2020;43:45–8. doi: 10.18773/austprescr.2020.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Idrees F, Jabeen K, Khan MS, Zafar A. Antimicrobial resistance profile of methicillin resistant staphylococcal aureus from skin and soft tissue isolates. J Pak Med Assoc. 2009;59:266–9. [PubMed] [Google Scholar]
- [14].Ahmad MK, Asrar A. Prevalence of methicillin resistant Staphylococcus aureus in pyogenic community and hospital acquired skin and soft tissues infections. J Pak Med Assoc. 2014;64:892–5. [PubMed] [Google Scholar]
- [15].Madzgalla S, Syed MA, Khan MA, Rehman SS, Müller E, Reissig A. et al. Molecular characterization of Staphylococcus aureus isolates causing skin and soft tissue infections in patients from Malakand, Pakistan. Eur J Clin Microbiol Infect Dis. 2016;35:1541–7. doi: 10.1007/s10096-016-2695-8. [DOI] [PubMed] [Google Scholar]
- [16].Zubair MH, Alvi S, Zubair MH. Skin and soft tissue infections. J Pak Med Assoc. 2010;60:513–4. [PubMed] [Google Scholar]
- [17].Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance in Pakistan: a systematic review of past decade. BMC Infect Dis. 2021;21:244. doi: 10.1186/s12879-021-05906-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Wayne P. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. Wayne, PA, USA: Clinical Laboratory Standard Institute; 2018. p. 296. [Google Scholar]
- [19].Weinstein M, Campeau S, Sharon C, Bobenchik A, Galas M, Gold H. Performance standards for antimicrobial susceptibility testing m100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. pp. 83–5. [Google Scholar]
- [20].Sah P, Khanal R, Upadhaya S. Skin and soft tissue infections: bacteriological profile and antibiotic resistance pattern of isolates. J Univers Coll Med Sci. 2013;1:18–21. [Google Scholar]
- [21].Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents. 2003;22:406–19. doi: 10.1016/s0924-8579(03)00154-7. [DOI] [PubMed] [Google Scholar]
- [22].Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60:1206–15. doi: 10.1093/jac/dkm357. [DOI] [PubMed] [Google Scholar]
- [23].Piéboji JG, Koulla-Shiro S, Ngassam P, Adiogo D, Njine T, Ndumbe P. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon. Int J Infect Dis. 2004;8:147–54. doi: 10.1016/j.ijid.2004.01.001. [DOI] [PubMed] [Google Scholar]
- [24].Ahmed A, Akram R, Ahmad S, Zaman AU, Ahmad N, Javed S, Aziz A. Prevalence of methicillin-resistant Staphylococcus aureus and other pathogens in pus samples of orthopedic department at a tertiary care hospital in Pakistan. Med J Indones. 2019;28:252–7. [Google Scholar]
- [25].Hafiz S, Hafiz AN, Ali L, Chughtai AS, Memon B, Ahmed A. et al. Methicillin resistant Staphylococcus aureus: a multicentre study. J Pak Med Assoc. 2002;52:312–5. [PubMed] [Google Scholar]
- [26].Ullah A, Qasim M, Rahman H, Khan J, Haroon M, Muhammad N. et al. High frequency of methicillin-resistant Staphylococcus aureus in Peshawar Region of Pakistan. SpringerPlus. 2016;5:600. doi: 10.1186/s40064-016-2277-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [27].Wu M, Tong X, Liu S, Wang D, Wang L, Fan H. Prevalence of methicillin-resistant Staphylococcus aureus in healthy Chinese population: a system review and meta-analysis. PloS one. 2019;14:e0223599. doi: 10.1371/journal.pone.0223599. [DOI] [PMC free article] [PubMed] [Google Scholar]